Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents
暂无分享,去创建一个
Woong Jung | Dong-Min Kim | Dong-Eun Kim | Dong-Eun Kim | W. Jung | Keun-Sik Kim | Dong-Min Kim | Minhee Kim | Keun-Sik Kim | Minhee Kim
[1] A. Hovanessian,et al. Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization , 2010, PloS one.
[2] W. Tan,et al. Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery , 2014, Journal of the American Chemical Society.
[3] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[4] Robert Langer,et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. , 2010, Nano letters.
[5] Koji Sode,et al. Screening and Improvement of an Anti-VEGF DNA Aptamer , 2010, Molecules.
[6] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[7] Anton P. McCaffrey,et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.
[8] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.
[9] Lawrence A. Yannuzzi,et al. PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[10] S. De Flora,et al. Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.
[11] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[12] Jørgen Kjems,et al. Characterisation of aptamer–target interactions by branched selection and high-throughput sequencing of SELEX pools , 2015, Nucleic acids research.
[13] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[14] W. Duan,et al. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. , 2013, Analytical chemistry.
[15] Kemin Wang,et al. Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.
[16] Koichi Abe,et al. Affinity improvement of a VEGF aptamer by in silico maturation for a sensitive VEGF-detection system. , 2013, Analytical chemistry.
[17] Robert Langer,et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.
[18] Xin Lu,et al. Novel MUC1 Aptamer Selectively Delivers Cytotoxic Agent to Cancer Cells In Vitro , 2012, PloS one.
[19] C H Heldin,et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. , 1996, Biochemistry.
[20] A. Debrabant,et al. Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice , 2014, PLoS neglected tropical diseases.
[21] C. Ferreira,et al. DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers , 2006, Tumor Biology.
[22] Srinivasan Ramachandran,et al. In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules , 2016, Scientific Reports.
[23] C. Sawyers. The cancer biomarker problem , 2008, Nature.
[24] You Han Bae,et al. Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[25] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[26] Theresa M Allen,et al. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.
[27] Paula J. Bates,et al. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin , 2006, Molecular Cancer Therapeutics.
[28] Weihong Tan,et al. Aptamer-modified gold nanoparticles for colorimetric determination of platelet-derived growth factors and their receptors. , 2005, Analytical chemistry.
[29] Chad A Mirkin,et al. Gold nanoparticles for biology and medicine. , 2010, Angewandte Chemie.
[30] Walhan Alshaer,et al. Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. , 2015, Bioconjugate chemistry.
[31] D. Josić,et al. Mammalian plasma membrane proteins as potential biomarkers and drug targets , 2011, Electrophoresis.
[32] J. Wengel,et al. By-Product Formation in Repetitive PCR Amplification of DNA Libraries during SELEX , 2014, PloS one.
[33] Jun‐Jie Zhu,et al. Versatile aptasensor for electrochemical quantification of cell surface glycan and naked-eye tracking glycolytic inhibition in living cells. , 2017, Biosensors & bioelectronics.
[34] T. Zhang,et al. Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.
[35] Daniel Agudelo,et al. Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications. , 2014, International journal of biological macromolecules.
[36] M. Stone,et al. In silico selection of RNA aptamers , 2009, Nucleic acids research.
[37] A. Pardi,et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[38] Robert M Hoffman,et al. The challenges posed by cancer heterogeneity , 2012, Nature Biotechnology.
[39] Dongsheng Liu,et al. DNA origami/gold nanorod hybrid nanostructures for the circumvention of drug resistance. , 2017, Nanoscale.
[40] B. Ristau,et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. , 2014, Urologic oncology.
[41] Avraham Rasooly,et al. Self-Assembled DNA Generated Electric Current Biosensor for HER2 Analysis. , 2017, Analytical chemistry.
[42] J. Burnett,et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells , 2013, Nucleic acids research.
[43] C. Esposito,et al. Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[44] Robert Langer,et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.
[45] Weihong Tan,et al. Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. , 2013, Journal of the American Chemical Society.
[46] Bertrand Tavitian,et al. Comparison of different strategies to select aptamers against a transmembrane protein target. , 2006, Oligonucleotides.
[47] Jie Gao,et al. PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. , 2017, Nanomedicine.
[48] Y. Assaraf,et al. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[49] John C. Chaput,et al. Analysis of aptamer discovery and technology , 2017 .
[50] Hideo Akiyama,et al. Intraocular injection of an aptamer that binds PDGF‐B: A potential treatment for proliferative retinopathies , 2006, Journal of cellular physiology.
[51] Cuichen Wu,et al. Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. , 2013, Journal of the American Chemical Society.
[52] Weihong Tan,et al. Generating aptamers for recognition of virus-infected cells. , 2009, Clinical chemistry.
[53] S. Jayasena. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.
[54] Xiaohong Fang,et al. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. , 2010, Accounts of chemical research.
[55] Jeff Zimmerman,et al. Crystal structure of NF-κB (p50)2 complexed to a high-affinity RNA aptamer , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[56] C. Benz,et al. Development of ligand-targeted liposomes for cancer therapy , 2004, Expert opinion on therapeutic targets.
[57] J. Rossi,et al. Current Advances in Aptamers for Cancer Diagnosis and Therapy , 2018, Cancers.
[58] Q. Yao,et al. Targeted drug delivery in pancreatic cancer. , 2010, Biochimica et biophysica acta.
[59] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[60] Xiaoling Zhang,et al. Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.
[61] J. Dannenberg,et al. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[62] Y. Zu,et al. A unique aptamer-drug conjugate for targeted therapy of multiple myeloma , 2016, Leukemia.
[63] H. Kourlas,et al. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. , 2006, Clinical therapeutics.
[64] P. Bouvet,et al. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. , 2010, Current opinion in molecular therapeutics.
[65] Y. Zu,et al. Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.
[66] E. Spicer,et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. , 2008, Cancer research.
[67] Yong-mei Song,et al. Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro , 2012, Journal of Translational Medicine.
[68] T. Lybrand,et al. Evoking picomolar binding in RNA by a single phosphorodithioate linkage , 2016, Nucleic acids research.
[69] S. M. Taghdisi,et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[70] Y. Jeong,et al. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. , 2010, ACS nano.
[71] B. Sullenger,et al. Identification and Characterization of an Agonistic Aptamer Against the T Cell Costimulatory Receptor, OX40 , 2022 .
[72] D. Richel,et al. The developing cancer stem-cell model: clinical challenges and opportunities. , 2012, The Lancet. Oncology.
[73] Hui Chen,et al. Molecular recognition of acute myeloid leukemia using aptamers , 2008, Leukemia.
[74] Zong-Hong Lin,et al. Aptamer-modified gold nanoparticles for targeting breast cancer cells through light scattering , 2009 .
[75] Xi‐lin Xiao,et al. A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy , 2015, PloS one.
[76] G. Mayer,et al. Molecular mechanism for inhibition of g protein-coupled receptor kinase 2 by a selective RNA aptamer. , 2012, Structure.
[77] Weihong Tan,et al. DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells , 2009, Proceedings of the National Academy of Sciences.
[78] J. McNamara,et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. , 2008, The Journal of clinical investigation.
[79] Chao Liang,et al. Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy , 2016, International journal of molecular sciences.
[80] B. Chabner,et al. Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.
[81] Dong-Eun Kim,et al. Comparison of Drug Delivery Efficiency between Doxorubicin Intercalated in RNA Aptamer and One Encapsulated in RNA Aptamer- Conjugated Liposome , 2015 .
[82] J. Katzenellenbogen,et al. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. , 2013, Journal of materials chemistry. B.
[83] Weian Zhao,et al. A polyvalent aptamer system for targeted drug delivery. , 2013, Biomaterials.
[84] B. Sullenger,et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. , 2008, Chemistry & biology.
[85] James O McNamara,et al. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. , 2015, Methods in molecular biology.
[86] John J. Rossi,et al. Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy , 2014, Molecular therapy. Nucleic acids.
[87] Yi Lu,et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.
[88] M. Gu,et al. Advances in aptamer screening and small molecule aptasensors. , 2014, Advances in biochemical engineering/biotechnology.
[89] S. Rottenberg,et al. New tools for old drugs: Functional genetic screens to optimize current chemotherapy , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[90] C. Ban,et al. Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer. , 2015, Biosensors & bioelectronics.
[91] Chen Wang,et al. Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro , 2011, PloS one.
[92] Weihong Tan,et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics , 2013, Proceedings of the National Academy of Sciences.
[93] D. Shangguan,et al. Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.
[94] Chao Liang,et al. Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers , 2016, International journal of molecular sciences.
[95] M. Ferrari,et al. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. , 2010, Biochemistry.
[96] Andrew D Ellington,et al. Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. , 2002, Nucleic acids research.
[97] R. Landgraf,et al. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[98] Edward Chu,et al. A history of cancer chemotherapy. , 2008, Cancer research.
[99] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[100] Zilong Zhao,et al. Nucleic acid aptamers: an emerging frontier in cancer therapy. , 2012, Chemical communications.
[101] Won Jong Kim,et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. , 2011, Biomaterials.
[102] D. Patel,et al. Adaptive recognition by nucleic acid aptamers. , 2000, Science.
[103] W. Duan,et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule , 2011, Cancer science.
[104] D. Shangguan,et al. Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.
[105] L. Garraway,et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma , 2014, Investigational New Drugs.
[106] Ge Zhang,et al. Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes , 2017, International journal of molecular sciences.
[107] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[108] E. Heydari-Bafrooei,et al. Electrochemical bioassay development for ultrasensitive aptasensing of prostate specific antigen. , 2017, Biosensors & bioelectronics.
[109] Robert Langer,et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.
[110] Yuan Zhang,et al. Progress in Aptamer-Mediated Drug Delivery Vehicles for Cancer Targeting and Its Implications in Addressing Chemotherapeutic Challenges , 2014, Theranostics.
[111] E. Gilboa,et al. CD28 Aptamers as Powerful Immune Response Modulators , 2013, Molecular therapy. Nucleic acids.
[112] J. Gariépy,et al. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers , 2015, Molecular therapy. Nucleic acids.
[113] D. Drolet,et al. An enzyme-linked oligonucleotide assay , 1996, Nature Biotechnology.
[114] Liyu Li,et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. , 2014, Biomaterials.
[115] S. Inogés,et al. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. , 2015, Biomaterials.
[116] N. Janjić,et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.
[117] G. Xiong,et al. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology , 2015, ACS nano.
[118] Ying Wang,et al. Aptamer-tagged DNA origami for spatially addressable detection of aflatoxin B1. , 2017, Chemical communications.
[119] P. Estrela,et al. Hybrid Synthetic Receptors on MOSFET Devices for Detection of Prostate Specific Antigen in Human Plasma. , 2016, Analytical chemistry.
[120] Xue Han,et al. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.
[121] J. McNamara,et al. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[122] T. Hoey. Drug Resistance, Epigenetics, and Tumor Cell Heterogeneity , 2010, Science Translational Medicine.
[123] V. Sridharan,et al. Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells , 2009, Molecular Pharmacology.
[124] D. Bunka,et al. Aptamers come of age – at last , 2006, Nature Reviews Microbiology.
[125] Anil Kumar,et al. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. , 2016, Biomaterials.
[126] Andrew D Ellington,et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.
[127] Tao Chen,et al. Aptamer-conjugated nanomaterials for bioanalysis and biotechnology applications. , 2011, Nanoscale.
[128] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[129] John I. Loewenstein,et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.
[130] Dong-Eun Kim,et al. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[131] Y. Hoshida,et al. Cancer biomarker discovery and validation. , 2015, Translational cancer research.
[132] M. Ashrafuzzaman. Aptamers as Both Drugs and Drug-Carriers , 2014, BioMed research international.
[133] Seok Chung,et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[134] Seonghwan Lee,et al. Aptamers and Their Biological Applications , 2012, Sensors.
[135] W. Duan,et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells , 2014, International journal of nanomedicine.